CFTR Modulators in Pregnancy and Postpartum

Region Stockholm75 enrolled

Overview

Observational study on women with Cystic Fibrosis treated with CFTR modulators during pregnancy and postpartum and their children. Registration on maternal health parameters and effects of CFTR-modulators in the newborn infant as well as effects of exposure through mother's own milk.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Cystic Fibrosis

Eligibility

Sex: ALLMax age: 50 Years

Medical Language ↔ Plain English

Inclusion Criteria: Woman with cystic fibrosis who is pregnant and treated with Kaftrio. Newborn infant to the above mentioned woman Exclusion Criteria: none

Locations (1)

Stockholm CF center

Stockholm, Sweden

RECRUITING

Outcomes

Primary Outcomes

Health effects in the newborn infant

Time frame: 6 years

Central Contacts

jenny svedenkrans

CONTACT

+46 8 123 80000 jenny.svedenkrans@regionstockholm.se

Terezia Pinzikova

CONTACT

+46 8 123 80000

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.